Abstracts tagged "remission"

Abstract Number: 121 • 2014 ACR/ARHP Annual Meeting
Predictors of Persistence of Power Doppler Ultrasound Synovitis in Rheumatoid Arthritis Patients in Clinical Remission
Nathalie Filippi¹, Cédric Lukas², Jacques Morel³, Bernard Combe⁴ and Gael Mouterde⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁵Immunologie Rhumatologie, Hopital Lapeyronie, Montpellier, France
Background/Purpose Ultrasound (US) is a sensitive tool for the evaluation of joint inflammation in patients with RA, and can detect synovitis even when clinical remission…
Abstract Number: 120 • 2014 ACR/ARHP Annual Meeting
Can We Use Ultrasound to Identify Rheumatoid Arthritis Patients in Remission Who Cannot Taper Their Medication?
Myrthe van der Ven¹, T. Martijn Kuijper¹, A. H. Gerards², Ilja Tchetverikov³, A.E.a.M. Weel^1,4, D. van Zeben⁵, J.M.W. Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ³Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands
Background/Purpose: Tapering medication in rheumatoid arthritis (RA) patients is becoming increasingly important due to the effectiveness of both biological therapy and tight-controlled treatment. Patients are…
Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
Abstract Number: 2870 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity and Serum Levels Of Angiogenic Factors In Patients With Rheumatoid Arthritis In Clinical Remission With Synovitis On Ultrasound
Julio Ramirez¹, Virginia Ruiz-Esquide², Isaac Pomés³, Raquel Celis⁴, Jaume Pomés³, Sonia Cabrera¹, M. Victoria Hernández⁵, Oscar M Epis⁶, Jose L. Pablos⁷, Raimon Sanmarti¹ and Juan D. Cañete², ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain, ³Radiology, Hospital Clínic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ⁵Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁶A.O. Ospedale Niguarda Cà Granda, Milan, Italy, ⁷Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose: To identify and characterize subclinical synovitis in patients with rheumatoid arthritis in clinical remission using power Doppler ultrasound and serum levels of angiogenic factors.…
Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Nevsun Inanc^1,2, Gülsen Ozen² and Haner Direskeneli³, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…
Abstract Number: 2276 • 2013 ACR/ARHP Annual Meeting
Does Socioeconomic Status Affect Outcomes In Early Rheumatoid Arthritis? Data From An Inception Cohort
Grace Yang¹, Vivian P. Bykerk², J. Carter Thorne³, Gilles Boire⁴, Diane Tin⁵, Carol A. Hitchon⁶, Edward Keystone⁷, Boulos Haraoui⁸ and Janet E. Pope⁹, ¹Medicine, Western University of Canada, London, ON, Canada, ²Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹St Joseph Health Care, London, ON, Canada
Background/Purpose: Assess the impact of socioeconomic status (SES) on outcomes in patients with early inflammatory arthritis using data from the Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 1522 • 2013 ACR/ARHP Annual Meeting
Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling¹, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Clinical Methodology Center, CHU, Besançon, France
Background/Purpose: Remission is the current target of management of chronic rheumatic diseases. Whereas in rheumatoid arthritis remission criteria have been recently proposed, in spondyloarthritis, no…
Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Boulos Haraoui¹, Algis V Jovaisas², William G. Bensen³, Rafat Y. Faraawi⁴, John T. Kelsall⁵, Sanjay Dixit⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, Francois Nantel⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1332 • 2013 ACR/ARHP Annual Meeting
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis
Elisa Gremese, Barbara Tolusso, Anna Laura Fedele, Maria Rita Gigante, Angela Carbonella, Silvia Canestri, Clara Di Mario and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Obesity per se is a systemic, low-grade inflammatory state and the adipose tissue is an endocrine organ that releases bioactive substances, including pro-inflammatory cytokines,…
Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Yukitomo Urata¹, Yoshihide Nakamura^2,3 and Ken-ichi Furukawa⁴, ¹Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ⁴Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…
Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 419 • 2013 ACR/ARHP Annual Meeting
A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Yukiko Kamogawa¹, Kyohei Nakamura², Ryu Watanabe², Tsuyoshi Shirai¹, Yoko Fujita³, Yuko Shirota⁴, Noriko Fukuhara¹, Hiroshi Fujii², Shinichiro Saito⁵, Tomonori Ishii² and Hideo Harigae², ¹Tohoku University, Sendai, Japan, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁴Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of hematology and rheumatology, Tohoku University, Sendai, Japan
Background/Purpose: Methotrexate (MTX) has been increasingly administered by patients with rheumatoid arthritis (RA). In rare cases, we experience development of malignant lymphoma in patients treated…
Abstract Number: 1011 • 2012 ACR/ARHP Annual Meeting
Structural Damage Is Reduced by Early Achievement of Clinical Remission
Paul Emery¹, Vibeke Strand², Andrew S. Koenig³, Ronald Pedersen³ and Eustratios Bananis⁴, ¹Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: The importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent structural damage is established.1 The objective of this…
Abstract Number: 809 • 2012 ACR/ARHP Annual Meeting
Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Ryusuke Yoshimi¹, Maasa Hama¹, Daiga Kishimoto¹, Reikou Watanabe¹, Takeaki Uehara², Yukiko Asami¹, Atsushi Ihata¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan
Background/Purpose: Although clinical remission is an agreeable goal of treatment in rheumatoid arthritis (RA), the definition is still controversial. Indeed, progressive structural damage is often…
Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Thomas J. A. Lehman¹, Emily Baird², Anusha Ramanathan³, Risa Alperin³, Emma J. MacDermott³, Alexa B. Adams³, Laura V. Barinstein³ and Lakshmi N. Moorthy⁴, ¹Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, ²Hospital for Special Surgery, NY, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].